Leveraging early markers of cystic fibrosis structural lung disease to improve outcomes
- PMID: 32245773
- DOI: 10.1183/13993003.00105-2020
Leveraging early markers of cystic fibrosis structural lung disease to improve outcomes
Conflict of interest statement
Conflict of interest: P.A. Flume has nothing to disclose. Conflict of interest: D.R. VanDevanter has nothing to disclose.
Comment on
-
Early markers of cystic fibrosis structural lung disease: follow-up of the ACFBAL cohort.Eur Respir J. 2020 Apr 3;55(4):1901694. doi: 10.1183/13993003.01694-2019. Print 2020 Apr. Eur Respir J. 2020. PMID: 31949117
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical